Shots:
- Daiichi Sankyo & AstraZeneca have reported topline P-III (DESTINY-Breast09) trial data on Enhertu (5.4mg/kg) ± pertuzumab vs taxane, trastuzumab & pertuzumab (THP) as a 1L treatment of HER2+ metastatic breast cancer pts (n=1157)
- Enhertu + pertuzumab showed improved PFS (1EP), with PFS benefit observed across all pre-specified subgroups during interim analysis; OS (2EP) remain immature but showed an early favorable trend. Data to be presented at future conferences & shared with regulatory authorities for potential approval
- 2nd cohort assessing Enhertu alone vs THP remains blinded to both pts & investigators & will proceed until the final PFS analysis
Ref: Businesswire | Image: Daiichi Sankyo & AstraZeneca
Related News:- AstraZeneca and Daiichi Sankyo Receive the EC’s Approval for Datroway to Treat HR+/HER2- Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
